Show/Hide Menu

MOR208

MOR208 is a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies.

MOR208 (formerly Xmab®5574) is a monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore an important factor for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), as well as chronic lymphocytic leukemia (CLL). Each year about 150,000 people are afflicted by B cell malignancies in the seven major markets.

Mode of action

FC-modification of MOR208 is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

CD19-expression on B cells

CD19 is expressed very broadly and early on B cells. Therefore it provides an ideal target for the treatment of B cell malignancies.

Clinical Studies

MOR208 is currently being investigated in clinical studies in the indications DLBCL and CLL. Here you can find further information on active clinical trials.

Background

In June 2010, MorphoSys AG and the Xencor, Inc. signed a worldwide exclusive license agreement for the antibody. The agreement provided MorphoSys with an exclusive worldwide license to Xmab®5574, which was subsequently renamed MOR208.

MOR208 was granted orphan drug designation in DLBCL (US and Europa) and CLL (US and Europe). Additionally, the FDA has granted fast track designation for the treatment of DLBCL.

Poster MOR208 subgroup analysis in NHL presented at the 2016 ASCO Annual Meeting
(PDF, 364 KB)
Poster planned combination trial MOR208 in CLL & SLL presented at the 2016 ASCO Annual Meeting
(PDF, 1 MB)
Oral presentation referring to MOR208 subgroup analysis, held at EHA 2016 by Dr. Wojciech Jurczak
(PDF, 1.1 MB)
Poster clinical phase 2 data of MOR208 in combination with lenalidomide in CLL presented at the 2015 ASH Annual Meeting (Ohio State University)
(PDF, 1 MB)